{"id":"nepa","rwe":[{"pmid":"41879714","year":"2026","title":"Structure-activity relationship of neplanocin A analogues for the identification of novel anti-HBV leads.","finding":"","journal":"Organic & biomolecular chemistry","studyType":"Clinical Study"},{"pmid":"41710598","year":"2026","title":"Netupitant/palonosetron is effective for preventing chemotherapy-induced nausea and vomiting in high-dose melphalan conditioning before autologous stem cell transplantation: A real-world analysis.","finding":"","journal":"Blood science (Baltimore, Md.)","studyType":"Clinical Study"},{"pmid":"41627515","year":"2026","title":"Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial.","finding":"","journal":"Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer","studyType":"Clinical Study"},{"pmid":"41552955","year":"2026","title":"Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+/HER2-low breast cancer.","finding":"","journal":"Future oncology (London, England)","studyType":"Clinical Study"},{"pmid":"41294153","year":"2026","title":"Light and Electron Microscopic Investigations of the Morphology of the Salivary Glands, Digestive Tract and Malpighian Tubules of the Aquatic Bug, Nepa cinerea Linnaeus, 1758 (Hemiptera: Nepidae).","finding":"","journal":"Microscopy research and technique","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"LOE Approaching","category":"status"},{"label":"Harrow Eye","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Capsular opacity","drugRate":"7.5%","severity":"common","organSystem":""},{"effect":"Decreased visual acuity","drugRate":"7.5%","severity":"common","organSystem":""},{"effect":"Foreign body sensation","drugRate":"7.5%","severity":"common","organSystem":""},{"effect":"Increased intraocular pressure","drugRate":"7.5%","severity":"common","organSystem":""},{"effect":"Sticky sensation","drugRate":"7.5%","severity":"common","organSystem":""},{"effect":"Conjunctival edema","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Corneal edema","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Dry eye","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Lid margin crusting","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Ocular discomfort","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Ocular hyperemia","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Ocular pain","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Ocular pruritus","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Photophobia","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Tearing","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Vitreous detachment","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"2.5%","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"2.5%","severity":"common","organSystem":""},{"effect":"Nausea/vomiting","drugRate":"2.5%","severity":"common","organSystem":""},{"effect":"Sinusitis","drugRate":"2.5%","severity":"common","organSystem":""}],"contraindications":["Blood coagulation disorder","Corneal epithelial degeneration","Corneal erosion","Corneal ulcer","Decreased Corneal Sensitivity","Diabetes mellitus","Impaired wound healing","Keratitis","Ocular Bleeding","Perforation of cornea","Rheumatoid arthritis","Tear film insufficiency"],"seriousAdverseEvents":[{"effect":"Increased bleeding time","drugRate":"","severity":"serious"},{"effect":"Delayed healing","drugRate":"","severity":"serious"},{"effect":"Corneal effects","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"Harrow Eye","patents":[{"applNo":"N021862","source":"FDA Orange Book","status":"Active","expires":"Jan 31, 2027","useCode":"U-1095","territory":"US","drugProduct":false,"patentNumber":"7834059","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NEPA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:48:54.744259+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T04:48:54.744155+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T04:49:07.680958+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:49:00.371511+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NEPA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:49:00.685806+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL299961/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:49:01.462795+00:00"}},"allNames":["nepa"],"offLabel":[],"synonyms":[],"timeline":[{"date":"2000-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from Chinese University of Hong Kong to Harrow Eye"},{"date":"2012-10-16","type":"positive","source":"FDA Orange Book","milestone":"Ilevro approved — 0.3%"}],"aiSummary":"NEPA, marketed by Harrow Eye, is a small molecule drug primarily indicated for post-op ocular inflammation. Its key strength lies in its specific mechanism of action, which targets a unique pathway in the body, potentially offering a differentiated therapeutic profile. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.","approvals":[],"ecosystem":[],"mechanism":{"target":"Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase","modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Nepa's exact mechanism of action is unknown, but as a small molecule drug, it is likely to interact with a specific protein or receptor in the body, potentially modulating its activity through allosteric or competitive binding."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=nepa","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=nepa","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:21:09.540020","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:49:07.681058+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"nepa","indications":{"approved":[{"name":"Post-Op Ocular Inflammation","diseaseId":"post-op-ocular-inflammation","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Postoperative Ocular Pain","diseaseId":"postoperative-ocular-pain","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"Harrow Eye","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03386617","phase":"PHASE2","title":"AKY15-HK-301_NEPA Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2018-02-27","conditions":["Breast Cancer"],"enrollment":55,"completionDate":"2028-12-31"},{"nctId":"NCT07132749","phase":"","title":"NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd","status":"ENROLLING_BY_INVITATION","sponsor":"Yeon Hee Park","startDate":"2025-08-12","conditions":["Patients With HER2-positive Advanced Breast Cancer Treated With T-DXd","Patients With HER2-low Advanced Breast Cancer Treated With T-DXd"],"enrollment":100,"completionDate":"2026-09-30"},{"nctId":"NCT04817189","phase":"PHASE4","title":"Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2021-02-01","conditions":["Chemotherapy-induced Nausea and Vomiting"],"enrollment":414,"completionDate":"2024-07-02"},{"nctId":"NCT07254416","phase":"PHASE4","title":"A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-15","conditions":["Breast Cancer Patients Treated With T-DXd"],"enrollment":120,"completionDate":"2027-06-30"},{"nctId":"NCT06904235","phase":"PHASE2","title":"Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)","status":"RECRUITING","sponsor":"Helsinn Healthcare SA","startDate":"2025-07-07","conditions":["Nausea and Vomiting Chemotherapy-Induced","Nausea Post Chemotherapy"],"enrollment":95,"completionDate":"2027-12"},{"nctId":"NCT06726291","phase":"PHASE4","title":"Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2024-02-26","conditions":["Endometrial Cancer"],"enrollment":84,"completionDate":"2026-06-30"},{"nctId":"NCT06417567","phase":"","title":"The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia Gastrointestinal Cancer Surgery: A Single-Center Retrospective Study","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-05-15","conditions":["General Anesthesia Gastrointestinal Cancer Surgery"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT06331520","phase":"PHASE3","title":"NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05-01","conditions":["Chemotherapy-induced Nausea and Vomiting","Highly Emetogenic Chemotherapy"],"enrollment":627,"completionDate":"2026-05-01"},{"nctId":"NCT03919058","phase":"NA","title":"Sit Less or Exercise More: Impact on Cardiometabolic Health in MS","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2019-04-13","conditions":["Multiple Sclerosis"],"enrollment":28,"completionDate":"2021-04-30"},{"nctId":"NCT03097588","phase":"PHASE2","title":"Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2017-04-27","conditions":["Malignant Neoplasm"],"enrollment":43,"completionDate":"2020-03-20"},{"nctId":"NCT03403712","phase":"PHASE3","title":"A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2018-03-16","conditions":["Chemotherapy-induced Nausea and Vomiting"],"enrollment":404,"completionDate":"2018-09-19"},{"nctId":"NCT04201769","phase":"PHASE3","title":"Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2016-11-25","conditions":["Chemotherapy-induced Nausea and Vomiting"],"enrollment":261,"completionDate":"2020-04"},{"nctId":"NCT03862144","phase":"PHASE2","title":"NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Consorzio Oncotech","startDate":"2016-05-12","conditions":["Chemotherapy-induced Nausea and Vomiting"],"enrollment":150,"completionDate":"2017-04-03"},{"nctId":"NCT03831633","phase":"PHASE4","title":"Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients","status":"UNKNOWN","sponsor":"VIFORFRANCE","startDate":"2018-09-19","conditions":["Oncology"],"enrollment":426,"completionDate":"2019-07-31"},{"nctId":"NCT02632487","phase":"NA","title":"Wearable Technology to Reduce Sedentary Behavior and CVD Risk in Older Adults","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-04","conditions":["Cardiovascular Diseases"],"enrollment":58,"completionDate":"2018-11-20"},{"nctId":"NCT02517021","phase":"PHASE3","title":"A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2015-11","conditions":["Chemotherapy-Induced Nausea and Vomiting"],"enrollment":405,"completionDate":"2016-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL299961"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Chinese University of Hong Kong","relationship":"Original Developer"},{"period":"present","companyName":"Harrow Eye","relationship":"Current Owner"}],"publicationCount":303,"therapeuticAreas":["Pain"],"biosimilarFilings":[],"originalDeveloper":"Chinese University of Hong Kong","recentPublications":[{"date":"2026 Mar 25","pmid":"41879714","title":"Structure-activity relationship of neplanocin A analogues for the identification of novel anti-HBV leads.","journal":"Organic & biomolecular chemistry"},{"date":"2026 Mar","pmid":"41710598","title":"Netupitant/palonosetron is effective for preventing chemotherapy-induced nausea and vomiting in high-dose melphalan conditioning before autologous stem cell transplantation: A real-world analysis.","journal":"Blood science (Baltimore, Md.)"},{"date":"2026 Feb 2","pmid":"41627515","title":"Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial.","journal":"Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer"},{"date":"2026 Feb","pmid":"41552955","title":"Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+/HER2-low breast cancer.","journal":"Future oncology (London, England)"},{"date":"2026 Apr","pmid":"41294153","title":"Light and Electron Microscopic Investigations of the Morphology of the Salivary Glands, Digestive Tract and Malpighian Tubules of the Aquatic Bug, Nepa cinerea Linnaeus, 1758 (Hemiptera: Nepidae).","journal":"Microscopy research and technique"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","brandName":"NEPA","companyName":"Harrow Eye","companyId":"harrow-eye","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:49:07.681058+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}